Objectives: To evaluate the influence of vancomycin dose, serum trough concentration, and dosing strategy on the evolution of acute kidney injury in critically ill patients. Design: Retrospective, single-center, observational study. 
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Some authors have proposed that doses more than 4 g/d, high serum trough concentrations, and an increased duration of vancomycin therapy are associated with nephrotoxicity (1, 11, 12) . To date, however, there is a relative paucity of largescale data able to measure the significance of vancomycin exposure as an independent risk factor for nephrotoxicity.
This study aimed to evaluate the influence of vancomycin dose, serum trough concentration, and dosing strategy on the evolution of acute kidney injury in critically ill patients.
MATERIALS AND METHODS
A retrospective cohort study was conducted on data from the University Hospital Birmingham, a tertiary referral and university-affiliated hospital. This ICU treats up to 80 critically ill patients at any one time and manages approximately 4,500 patients annually. The ICU provides local and tertiary care for all adult specialties, including heart, lung, liver, kidney, and bone marrow transplantation. The data of all patients who received IV vancomycin from December 1, 2004 , to August 31, 2009, were extracted from a central database. The data of patients receiving vancomycin by non-IV routes were not included in the primary database.
Local protocol dictated that patients with a central venous catheter receive vancomycin by continuous infusion. No criteria were established as to which patients should receive vancomycin by intermittent infusion, but typically, this would occur if 1) the clinician was not compliant with the protocol or 2) no central catheter was present. Data of those patients by which the dosing method was unknown or those patients who received vancomycin by both continuous and intermittent infusion were included in interests of maximizing available data. If a patient was the recipient of an intermittent infusion, serum concentrations were measured within 30 minutes of the next dose. If the patient was on continuous infusion, the samples were taken randomly, but at least 18 hours after the preceding dose change.
The study was approved by the South Birmingham Research Ethics Committee (09/H1207/140). Data extracted from the hospital's electronic database included sex, weight (where available), date of birth, ethnicity, hospital and ICU admission dates, ICU and hospital discharge dates, hospital discharge status, time of vancomycin prescription, administration start times, rate of infusion, dosage, serum creatinine concentration at admission, serum creatinine concentration during vancomycin therapy, trough serum vancomycin concentration, and MRSA status. If multiple trough serum vancomycin concentrations were available, the median and maximum measured concentrations were recorded.
As rifampicin's pulmonary penetration is often considered superior to vancomycin (13) , any concomitant prescription was included in the analysis to measure effects it may have on clinical outcome. Furthermore, given reports of rifampicin renal toxicity (14, 15) , inclusion allowed analysis of its influence on renal function when prescribed simultaneously with vancomycin. Given patients included in the analysis were admitted to the ICU, inotrope data were collected to account for potential confounding effects on renal function. Sequential Organ Failure Assessment (SOFA) (3, 16) data were also collected at the start of treatment. With the exception of Glasgow Coma Scale (GCS) and blood pressure, all components (ventilation status, worst daily Po 2 /Fio 2 ratio, highest inotrope use, liver function, platelet count, and creatinine concentrations) of the SOFA score were calculated using data collected from the same electronic database.
Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula (4, 17) for all serum creatinine concentrations obtained throughout the ICU stay. The primary endpoint, new onset nephrotoxicity, was defined as an increase in serum creatinine concentration more than or equal to 50%, a decrease in eGFR more than or equal to 25%, or a serum creatinine concentration more than or equal to 350 μmol/L (in the setting of an acute increase ≥ 44 μmol/L) as per the RIFLE acute kidney injury classification system (18) . Secondary endpoints were death within 72 hours of the last recorded vancomycin dose (irrespective of treatment modality), all-cause mortality, and a combined endpoint of either death within 72 hours of vancomycin administration or nephrotoxicity.
The prevalence of new onset nephrotoxicity was reported, and univariate analysis was performed to determine data distribution and the prevalence of missing data. Data for which no serum vancomycin concentration, dosing amount, or creatinine concentration were available (n = 755) or which had incomplete SOFA score availability (n = 356) were excluded from analysis. Furthermore, where unique patients had multiple ICU admissions during the study period (n = 151), only data from the first episode were used. Continuous variables with a normal distribution are reported as mean ± sd and nonnormal variables are reported as median and interquartile range. The Pearson product-moment correlation coefficient was used to identify highly correlated potential predictive variables (r > 0.8) with the variable most predictive of nephrotoxicity included in further analysis. Predictive variables associated with the primary and secondary endpoints were explored using logistic regression analysis. Manual and backward stepwise techniques were used to identify the model with best fit. Interactions between predictive variables were included where multivariate and bivariate findings differed and inclusion of the interaction improved goodness-of-fit. Independent predictive variables with a p value of less than 0.05 were considered statistically significant. Goodness-of-fit was assessed by the Hosmer and Lemeshow statistic and the Nagelkerke R 2 index. Receiver operating characteristic (ROC) curves were used to explore thresholds for nephrotoxicity at different highest measured and median serum vancomycin concentrations. Youden index was used to identify the optimal threshold for maximizing sensitivity and specificity at specific threshold values. Statistical analysis was performed in SPSS (Version 20.0; IBM, Armonk, NY).
RESULTS
During the study period, 2,359 patients were prescribed vancomycin therapy in line with the study inclusion criteria. Of these, 2,208 were primary admissions, of which 1,430 had complete datasets (65%). Univariate analysis comparing excluded and included patients showed no significant differences between age at admission (p = 0.055), day 1 MDRD (p = 0.319), or weight (p = 0.349) ( Table 5 summarizes the risk of nephrotoxicity, sensitivity, and specificity for incremental increases in trough serum vancomycin concentration.
Predictors of Nephrotoxicity
The most parsimonious logistic regression model identified duration of therapy in days (odds ratio [OR] = 1.041; p < 0.001), simultaneous vasoactive therapy (OR = 1.633; p < 0.001), and median trough serum vancomycin concentration (OR = 1.112; p < 0.001) as independent positive predictors of nephrotoxicity ( Table 6 ). Intermittent infusion was associated with a significantly greater risk of nephrotoxicity than continuous infusion (OR = 8.204; p < 0.001). There was, however, a significant interaction between median serum vancomycin concentration and infusion method. A 1 mg/L increase in the median serum vancomycin concentration 
DISCUSSION
There are few large-scale studies examining the influence of vancomycin therapy on nephrotoxicity in critically ill patients. The need to better understand the vancomycin exposure-toxicity relationship is important, given recent guidelines advocating higher serum trough concentrations to counter the decreasing susceptibility of MRSA (9, 10) . In this study of 1,430 critically ill patients, we found that elevated median trough serum vancomycin concentration is associated with a significant increase in risk of nephrotoxicity with each 1 mg/L increase in concentration associated with a 11.2% increase in the odds of nephrotoxicity. Duration of therapy was also positively predictive of nephrotoxicity with every 1-day increase in the duration of therapy being associated with a 4.1% increase in the odds of nephrotoxicity. These findings are in concordance with other studies that show duration of vancomycin therapy to have a significant positive association with nephrotoxicity (12, 19, 20) . Of interest, Pritchard et al (11) noted a significant rising trend in vancomycin serum concentrations (p < 0.001) without an increase in the prevalence of nephrotoxicity during the same period. This finding, however, may be confounded by the association of increasing serum trough concentrations with a decreasing duration of therapy during the same period. We hypothesize that if organisms with reduced susceptibility to vancomycin continue to become more prevalent, then the potential combination of increased duration of treatment and higher trough serum concentrations may result in a further increased prevalence of nephrotoxicity.
We found that continuous infusion was significantly less likely to cause nephrotoxicity in multivariate analysis than all other infusion types despite patients on continuous infusion receiving greater daily doses than those receiving intermittent infusion of vancomycin. Patients who received intermittent infusion had an 8.2 times higher odds of nephrotoxicity than those who received continuous infusion, and this effect was independent of baseline renal function and serum vancomycin concentration. This confirms the conclusion reached in a recent meta-analysis that suggested continuous infusion is associated with a significantly reduced risk of nephrotoxicity compared with intermittent infusion (relative risk = 0.6; 95% CI, 0.4-0.9; p = 0.02) (21) . Furthermore, mixed and unknown dosing strategies were associated with lower odds of nephrotoxicity than intermittent infusion. This is expected, due to the fact that the latter categories likely consist of a large proportion of patients dosed by continuous infusion in accordance with unit protocol. Furthermore, it has been shown that up to 66% of patients receiving intermittent infusion do not reach target concentrations compared with 30% of patients who receive continuous infusion (22) . Given the rise in trough concentration recommendations over the study period (10), the intermittent infusion group may have simply been undertreated.
The higher prevalence of nephrotoxicity in the continuous infusion group compared with the intermittent infusion group (24.7% vs 19.7%) in bivariate analysis deserves mention as this suggests the possibility of confounding. As described above, the median serum vancomycin concentration was significantly higher in patients receiving continuous infusion, and this was identified as the main factor hypothesized to be responsible for this confounding effect (Table 4 ). In addition, there was a significant interaction between median serum vancomycin concentration and infusion method in multivariate analysis, such that an increase in median serum concentration was associated with a higher odds of nephrotoxicity in those who received vancomycin by continuous infusion compared with those with intermittent infusion. As discussed previously, 66% of patients receiving intermittent infusion do not reach target concentrations. Therefore, it could very well be that a shift to the right in the serum concentration curve is increasing the influence that median serum trough concentration has on nephrotoxicity in the continuous infusion group. Again, AUC would be ideal to study this relationship. To our knowledge, this is the first large-scale study that has shown vancomycin administration by continuous infusion is associated with decreased nephrotoxicity. Unfortunately, the decrease in acute kidney injury associated with continuous infusion does not translate to improved mortality. Intermittent infusion was associated with a nonsignificant lower odds of mortality than continuous infusion (p = 0.141). A greater percentage of the cohort received continuous infusion (Table 2) , and the duration of treatment and median SOFA score were both higher in the continuous infusion group (Table 4) , alluding to potential nonmeasured factors confounding the result. Given local protocol dictates that prescription of vancomycin by continuous infusion can only be administered by central catheter, and inherently, a patient requiring central access is likely to have greater morbidity, continuous infusion being more predictive of mortality than intermittent infusion in this cohort is not surprising. A large prospective study is required to categorically determine the effect of treatment method on mortality.
In addition to being associated with nephrotoxicity, duration of vancomycin therapy also appears positively predictive of all-cause mortality. We are, however, unable to speculate on why this is the case as information on the indication for vancomycin therapy, infection site, and sensitivities of the targeted organism are unknown. These factors may all contribute to extended vancomycin regimens in the context of greater morbidity. It is interesting to note that although nephrotoxicity was positively associated with mortality in the enter model, it was not included in the final logistic regression model due to poor significance. We hypothesize that follow-up at 28 days, or latter, would identify this trend as significant.
The analysis included in this study provided interesting results. In phase 1 of their study, Pritchard et al (11) showed that a median trough vancomycin serum concentration of 14 mg/L was the threshold for development of nephrotoxicity. Here, we have shown that maximum sensitivity and specificity for nephrotoxicity occurred at a median concentration of 17.8 mg/L. Though not a large increase in concentration compared to Pritchard et al (11) , our study suggests that the lower spectra of recommended serum concentrations are relatively safe. In clinical practice, the median concentration is not prospectively useful. We found the threshold for nephrotoxicity is 23.7 mg/L when considering the highest measured serum concentration observed for a single patient. A prudent clinician, with the aid of therapeutic drug monitoring (TDM), thus has the potential to negate significant risk of nephrotoxicity by ensuring measured concentrations do not surpass these values. Furthermore, it is clear that greater concentrations do have an association with nephrotoxicity (Table 5) , and this must be considered when targeting high serum concentrations to circumvent the challenge of a high minimum inhibitory concentration (MIC). As MRSA MICs continue to rise, it will be necessary to look to other agents for therapeutic purposes, particularly if the clinical context deems the risk of acute kidney injury not tolerable to the patient. It must be recognized that this study is limited by its retrospective nature, and as such, causality cannot be demonstrated. An inherent flaw of retrospective data analysis is the difficulty to account for all potential confounding variables and simultaneous treatment agents. A prospective randomized controlled trial is necessary to confirm these results. Although we are able to explore factors associated with nephrotoxicity in patients receiving vancomycin, we are unable to quantify the overall risk of nephrotoxicity associated with vancomycin use in a general ICU population. We also acknowledge that SOFA has not been validated for tracking the severity of illness in ICU. Despite this, inclusion of this SOFA score allowed for the degree of morbidity to be partially accounted for in the multivariate analysis. Furthermore, the titration of vancomycin dosing based on MDRD determinations of eGFR is not validated and may not be optimal. Finally, generalizability to other ICU population groups needs to be ensured by validation with an independent dataset. In summary, we have shown that trough serum vancomycin concentrations and duration of therapy are associated with increased risk of nephrotoxicity. Further, baseline organ function (SOFA) and simultaneous vasoactive therapy are predictive of nephrotoxicity. Given recommendations to increase serum vancomycin concentrations to 15-20 mg/L to combat rising MICs, this information reinforces the valuable role that TDM plays in optimizing safe vancomycin therapy. We have also demonstrated that continuous infusion is associated with significantly less nephrotoxicity than dosing by intermittent infusion. Despite this, there is still a lack of data showing whether the method of administration impacts on all-cause mortality and resolution of infection, despite our results showing a small nonsignificant trend toward survival advantage in the intermittent infusion cohort. Given that continuous infusion is associated with decreased nephrotoxicity, reaches target concentrations faster with fewer samples (when loading doses are used) (23, 24) , has less variability in the daily infused dose, reduces costs (25) , and has less variability in serum concentrations (26) , this large dataset supports the use of continuous infusion of vancomycin in critically ill patients.
